China's Landwind Device Maker Reported Target Of U.S. Acquisition
This article was originally published in PharmAsia News
Executive SummaryChinese medical-device maker Landwind is said to be the target of an acquisition effort by the U.S.-based hedge fund, Avenue Capital
You may also be interested in...
Brinavess Rejected By Advisory Cmte., Leaving US FDA To Mull Lifting Clinical Hold On Correvio's AFib Drug
Revised North American trade deal touted as enabling Congress to address crisis of high drug prices; requirement for 10 years biologic exclusivity is removed and language to allow incentives for generics added.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.